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between the compliant/persistent and non-compliant/non-persis-
tent groups for other cardiovascular risk factors (age, diabetes,
smoking status, cholesterol, and alcohol). RESULTS: Compliant
patients (those with medication-possession ratios >80%) had 12-
month average systolic and diastolic BP values 3.5mmHg (p <
0.0005) and 0.5mmHg (non-signiﬁcant) lower, respectively, than
those of non-compliant patients. Assuming these differences
remain over time, the Glynn algorithms predict a 4.6% decrease
(95% conﬁdence interval 2.4%, 6.9%) in the relative risk of
adverse cardiovascular outcomes for men and a 16.3% decrease
(95% CI 12.2%, 20.6%) for women. Persistent patients (those
remaining on valsartan therapy for 12 months) had ﬁnal systolic
and diastolic BP values 4.1mmHg and 2.5mmHg (both p < 0.05)
lower than those for non-persistent patients, projecting an 8.4%
decrease (95% CI 3.1%, 13.9%) in relative risk of adverse car-
diovascular outcomes for men and a 26.6% decrease (95% CI
19.8%, 33.9%) for women. CONCLUSIONS: Compliance with
and persistence to hypertension therapy predicted substantial
decreases in adverse cardiovascular outcomes. These impacts
may also lead to improved patient-reported outcomes and
decreased costs, and can be used to assess long-term treatment
cost-effectiveness.
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OBJECTIVE: To determine the impact of adherence to antihy-
perlipidemic drug therapy on patients’ total pharmacy and
medical costs, from the payer’s perspective. METHODS: Retro-
spective database analysis of Maryland Medicaid medical and
pharmacy claims for the period January 1, 2001–December 31,
2003. Inclusion criteria: Continuously enrolled patients older
than 18 years who had at least one prescription claim for any of
the statins. Exclusion criteria (to obtain incident cohort): Patients
who had at least a claim before July 1st, 2002. Non-adherence
was deﬁned as a failure to reﬁll a prescription claim. General-
ized linear models with a logarithmic link function were used to
determine the impact of adherence to statins on medical costs,
after adjusting for age, gender, race and comorbidities by con-
structing a Charlson Comorbidity Index. RESULTS: Total of
2746 patients, 34% male, 44% African-Americans, and 65%
older than 63. Patients who adhere to their antihyperlipidemic
pharmacotherapy incur 26.08% (p < 0.0001; CI -0.41, -0.19)
and 33.25% (p = 0.0002; CI -0.62, -0.19) lower total costs
(pharmacy and medical) and medical costs respectively than
those who do not. Those between the age of 40 and 63 and those
who are African-American incur 19.22% (p < 0.0001; CI -0.31,
0.11) and 14.05% (p = 0.002; CI -0.25, -0.05) lower total costs
than those who are older than 63 and those who are Caucasian
respectively. A unit increase in the comorbidity index leads to a
10.13% (p < 0.0001; CI 0.07, 0.12) increase in total costs. CON-
CLUSIONS: On average, adherence to antihyperlipidemic phar-
macotherapy results in lower total costs. More awareness given
to adherence patterns on statins could lower the payers’ total
medical costs.
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OBJECTIVE: To identify the determinants of drug adherence
among statin users in a Medicaid managed care population.
METHODS: Retrospective database analysis of Maryland 
Medicaid medical and pharmacy claims for the period January
1, 2001–December 31, 2003. Inclusion criteria: Continuously
enrolled patients older than 18 years who had at least one pre-
scription claim for any of the statins. Exclusion criteria (to obtain
incident cohort): Patients who had at least a claim before July
1st, 2002. Non-adherence was deﬁned as a failure to reﬁll a pre-
scription claim. Logistic regression models were built to deter-
mine the association of age, gender, race, and comorbidities
(based on Charlson Comorbidity Index) with drug adherence.
RESULTS: Out of 1997 patients, 61% females, 57% African
Americans, and 70% 60 years old or younger. Caucasians were
more adherent than African Americans (30% vs. 22%), younger
patients less adherent than older patients (24% vs. 26%) and
females less adherent than males (22% vs. 28%). In the logistic
multivariate model, adjusting for demographics and comorbidi-
ties, African Americans (OR 0.68, 95% CI 0.549, 0.841), and
males (OR 1.33, 95% CI 1.083, 1.641) were signiﬁcantly more
likely to adhere to statin therapy. CONCLUSION: In this Med-
icaid population, adherence to statin pharmacotherapy is lower
among females and African Americans. The effectiveness of
adherence programs may be improved if they are earmarked to
these speciﬁc subpopulations.
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OBJECTIVE: To identify patient segments based on beliefs about
medications, reasons for non-adherence, and demographics to
inform actionable adherence improvement messaging.
METHODS: A total of 5630 patients self-identifying as having
high cholesterol responded to the Thomson Medstat PULSE con-
sumer health behavior survey in October–November 2005.
These respondents received cholesterol-speciﬁc questions about
their adherence, beliefs and reasons for non-adherence. Beliefs
about the necessity of and concerns about taking cholesterol-
lowering medications were assessed via ﬁve likert-scale ques-
tions, each with summed scores ranging between 5 and 25. A
cut-point of 15 was used to identify high versus low necessity 
or concern creating four patient segments: high necessity/
high concern (HNHC), low necessity/high concern (LNHC), low
necessity/low concern (LNLC), high necessity/low concern
(HNLC). Non-adherence was measured as skipping, taking
smaller doses, delaying, and/or stopping medication ﬁlls in the
past 30 days. Reasons for non-adherence included: cost, forget-
ting, experience with the medication, self-assessed need, and 
convenience. RESULTS: A total of 4737 respondents reported
taking prescription cholesterol-lowering medications with
28.1% reporting non-adherence. Non-adherence rates varied sig-
niﬁcantly among patient segments: 51.6% of LNHC respon-
dents, 36.1% of HNHC, 29.1% of LNLC and 20.8% of HNLC
were non-adherent (chi-square p < 0.0001). Type of and reasons
for non-adherence also varied. Patients with high concerns were
more likely to report taking smaller doses (33.5% of HNHC and
36.5% of LNHC versus 22.4% of LNLC and 20.6% of HNLC)
than those with low concerns and they were more likely to be
non-adherent due to experiences with medications (26.6% of
HNHC and 30.2% of LNHC versus 12.2% LNLC and 8.7% of
HNLC). Patient segments also differed by income (chi-square p
< 0.0001), education (chi-square p < 0.0001), and health status
(chi-square p < 0.0001). CONCLUSION: Creating psycho-
graphic patient segments using patient beliefs about medication
